1 / 42

Expanding the PsA Armamentarium

Expanding the PsA Armamentarium. GRAPPA Treatment Recommendations for Psoriatic Arthritis. Controlled Trials of DMARDs in Psoriatic Arthritis. Anti-TNF Therapies in PsA ACR and PASI Responses. Anti-TNFs in PsA Other Outcomes. Current RA Therapies: Can They Be Used in PsA?.

april-casey
Download Presentation

Expanding the PsA Armamentarium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Expanding the PsA Armamentarium

  2. GRAPPA Treatment Recommendations for Psoriatic Arthritis

  3. Controlled Trials of DMARDs in Psoriatic Arthritis

  4. Anti-TNF Therapies in PsAACR and PASI Responses

  5. Anti-TNFs in PsAOther Outcomes

  6. Current RA Therapies: Can They Be Used in PsA?

  7. Abatacept in PsAACR and PASI Responses at 169 Days

  8. Emerging Therapies for PsA

  9. Emerging Therapies for PsA (cont)

  10. T-Cell Differentiation Pathways

  11. IL-23 and Resident T Cells Promote Enthesitis and Osteoproliferation

  12. Ustekinumab Inhibits IL-12 and IL-23 by Targeting the p40 Subunit

  13. PSUMMIT 1: Ustekinumab (IL-12/23i) in Psoriatic ArthritisACR20/50/70 Responders at Week 24

  14. PSUMMIT2Efficacy of Ustekinumab in Psoriatic Arthritis at 24 Weeks

  15. Change From Baseline in Modified Total vdH-S Score at 24 Weeks

  16. TH17 CellsElevated in Patients With Psoriatic Arthritis

  17. Psoriatic Arthritis Synoviocytes Express High Levels of IL-17RA

  18. IL-17 Inhibitors in Development for PsA

  19. Efficacy of IL-17 Inhibitors in Plaque Psoriasis

  20. BrodalumabACR Responses at 24 Weeks

  21. Mean Change in DAS28 to 52 WeeksObserved Analysis

  22. Mean Change From Baseline in Dactylitis and EnthesitisObserved Analysis

  23. IL-6 Cell Types and Biologic Activities

  24. Cytokine Signaling Pathways

  25. ApremilastPDE4 inhibitor

  26. PALACE 1Apremilast in PsA

  27. Efficacy of Tofacitinib in Psoriasis

  28. Abbreviations

  29. Abbreviations (cont)

  30. Abbreviations (cont)

  31. References

  32. References (cont)

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

  38. References (cont)

  39. References (cont)

More Related